The Next Billion-Dollar Opportunity in Alzheimer's Disease Market: 6 Pipeline Therapies to Watch | DelveInsight

The Alzheimer’s market is projected to grow from about $4B in 2025 to expand at a 22.7% CAGR through 2036, driven by disease-modifying anti-amyloid therapies and broader adoption from biomarker-based earlier diagnosis. Key momentum includes LEQEMBI (lecanemab) gaining regulatory strength and an anticipated approval of a subcutaneous maintenance formulation (IQLIK) to reduce infusion reliance, alongside KISUNLA (donanemab) offering a potential discontinue-after-amyloid-clearance path. The article also highlights a widening late-stage pipeline (e.g., Suven’s Masupirdine, Roche’s Trontinemab, and BMS’ COBENFY) with multiple topline readouts between 2026–2029, supporting a constructive outlook for future launches.

Analysis

The investable edge is not the broad Alzheimer’s TAM story; it is where the workflow friction sits. The biologic winners are the names that reduce administration burden and improve persistence, because reimbursement and clinic capacity—not just efficacy—will determine share. That structurally favors the large-cap incumbents with commercialization muscle and safety/monitoring infrastructure, while leaving most precommercial pipeline names as narrative stocks until they print reproducible data.

Over the next 1-3 months, the market is likely to trade on read-throughs from launch logistics, not on the long-dated market-size thesis. Convenience upgrades can matter more than incremental efficacy if they lower visit intensity and widen the prescriber base, which is why maintenance-format assets and oral symptomatic agents have cleaner near-term monetization paths than disease-modifying candidates still waiting on validation. The second-order winner set includes neurology practices, biomarker testing, and specialty distribution; the loser set includes smaller developers that need capital markets to stay open.

The contrarian risk is that the current optimism overstates adoption speed. Early-stage AD care is bottlenecked by diagnosis, ARIA monitoring, and patient selection, so uptake can lag even after approval; if safety headlines worsen or payers tighten prior auth, sentiment can reverse quickly. That argues for owning quality franchises and treating small-cap pipeline names as event-driven trades rather than long-duration investments.

Key Decisions for Investors

• Long LLY on 3-6 month weakness; it is the cleanest quality exposure to any expansion in treated AD patients, with upside if convenience improves persistence. Falsifier: any real-world adoption or safety evidence showing discontinuation/churn remains high.
• Long AXSM into the next agitation-data/catalyst window with a defined-risk call spread rather than stock; the asset has a nearer monetization path than disease-modifying peers, but only if clinical execution holds. Falsifier: missed efficacy signal or adverse-tolerability readout.
• Long ACAD as a more defensive neuropsychiatry exposure versus pure AD-beta; it benefits if clinicians prioritize symptom control before expensive biologic initiation. Falsifier: weak uptake versus existing standards or payer pushback.
• Pair trade: long LLY / short ANVS for 1-3 months to express quality-versus-binary execution risk. The long leg captures commercialization leverage; the short leg monetizes the market’s tendency to overcapitalize early-stage pipeline optimism. Falsifier: unexpectedly strong confirmatory trial data from ANVS.
• No new position in RHHBY until a clearer filing/timeline update; keep as a watchlist name only. The thesis is long-dated and should not be forced before regulatory visibility improves.